Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Homeopathic Claims Go Under FTC Microscope, Potential For Regulatory Shift Magnifies

This article was originally published in The Pink Sheet Daily

Executive Summary

FTC says the homeopathic market “shifted from one based primarily on formulations prescribed for an individual user to mass-market formulations widely advertised and sold nationwide in major retail stores.” The workshop could signal FTC interest in asking for clinical trials to support for OTC homeopathic claims.

You may also be interested in...

Homeopathic Regulatory Evaluation Stocked With FDA Concerns, Industry Answers

The industry wants FDA to consider that a fraction of poison control reports are for homeopathics compared to other drugs and the agency’s current enforcement authorities maintain compliance in manufacturing and marketing the products. FDA is considering whether to maintain its policy that recognizes an ingredient’s inclusion in the HPUS monograph as pre-market approval.

Homeopathic Claims Have FTC Searching For Remedy To Regulatory Conflict With FDA

FTC shuts down the second marketer this year for making fraudulent claims for human chorionic gonadotropin weight-loss products. Enforcing against other homeopathics’ claims that violate advertising regulations, however, is on hold until FTC resolves its differences with FDA’s regulatory oversight of the products.

US DoJ Has 'Key Focus' On Supplement Industry, Adds 6 Attorneys To Sector

"It is just common sense that there's going to be fraud where you have the combination of high growth, developing science, imported products or ingredients and limited oversight," says David Morrell, deputy assistant US attorney in DoJ'd Consumer Protection Branch. CPB is adhering to executive order President Trump made earlier in 2019 instructing federal agencies to enforced based on regulations, not on guidance.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts